Literature DB >> 17855534

Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.

Wendy M Blay1, Theresa Kasprzyk, Lynda Misher, Barbra A Richardson, Nancy L Haigwood.   

Abstract

The design of an efficient human immunodeficiency virus (HIV) immunogen able to generate broad neutralizing antibodies (NAbs) remains an elusive goal. As more data emerge, it is becoming apparent that one important aspect of such an immunogen will be the proper representation of the envelope protein (Env) as it exists on native virions. Important questions that are yet to be fully addressed include what factors dictate Env processing, how different Env forms are represented on the virion, and ultimately how these issues influence the development and efficacy of NAbs. Recent data have begun to illuminate the extent to which changes in gp41 can impact the overall structure and neutralizing sensitivity of Env. Here, we present evidence to suggest that minor mutations in gp120 can significantly impact Env processing. We analyzed the gp120 sequences of 20 env variants that evolved in multiple macaques over 8 months of infection with simian/human immunodeficiency virus 89.6P. Variant gp120 sequences were subcloned into gp160 expression plasmids with identical cleavage motifs and gp41 sequences. Cells cotransfected with these plasmids and delta env genomes were able to produce competent virus. The resulting pseudoviruses incorporated high levels of Env onto virions that exhibited a range of degrees of virion-associated Env cleavage (15 to 40%). Higher levels of cleavage correlated with increased infectivity and increased resistance to macaque plasma, HIV immunoglobulin, soluble CD4, and human monoclonal antibodies 4E10, 2F5, and b12. Based on these data, we discuss a model whereby changes in gp120 of 89.6P impact Env processing and thereby mediate escape from a range of neutralizing agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855534      PMCID: PMC2169095          DOI: 10.1128/JVI.01215-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  83 in total

1.  Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.

Authors:  B Chackerian; L M Rudensey; J Overbaugh
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Authors:  P W Parren; I Mondor; D Naniche; H J Ditzel; P J Klasse; D R Burton; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

Authors:  J D Thompson; T J Gibson; F Plewniak; F Jeanmougin; D G Higgins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

4.  HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import.

Authors:  R A Fouchier; B E Meyer; J H Simon; U Fischer; M H Malim
Journal:  EMBO J       Date:  1997-08-01       Impact factor: 11.598

5.  The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells.

Authors:  J H Simon; R A Fouchier; T E Southerling; C B Guerra; C K Grant; M H Malim
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.

Authors:  G B Karlsson; F Gao; J Robinson; B Hahn; J Sodroski
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations.

Authors:  P Gluschankof; I Mondor; H R Gelderblom; Q J Sattentau
Journal:  Virology       Date:  1997-03-31       Impact factor: 3.616

8.  Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.

Authors:  J W Bess; R J Gorelick; W J Bosche; L E Henderson; L O Arthur
Journal:  Virology       Date:  1997-03-31       Impact factor: 3.616

9.  Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.

Authors:  H Mo; L Stamatatos; J E Ip; C F Barbas; P W Parren; D R Burton; J P Moore; D D Ho
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

10.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

View more
  18 in total

1.  Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission.

Authors:  Viv Peut; Shahan Campbell; Adriana Gaeguta; Rob J Center; Kim Wilson; Sheilajen Alcantara; Caroline S Fernandez; Damian F J Purcell; Stephen J Kent
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

2.  Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

Authors:  Ann J Hessell; Sean McBurney; Shilpi Pandey; William Sutton; Lily Liu; Liuzhe Li; Maxim Totrov; Susan Zolla-Pazner; Nancy L Haigwood; Miroslaw K Gorny
Journal:  Vaccine       Date:  2016-04-19       Impact factor: 3.641

3.  The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.

Authors:  Nicholas M Provine; Valerie Cortez; Vrasha Chohan; Julie Overbaugh
Journal:  Virology       Date:  2012-02-25       Impact factor: 3.616

4.  Unraveling the entry mechanism of baculoviruses and its evolutionary implications.

Authors:  Manli Wang; Jue Wang; Feifei Yin; Ying Tan; Fei Deng; Xinwen Chen; Johannes A Jehle; Just M Vlak; Zhihong Hu; Hualin Wang
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

5.  HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.

Authors:  Briana Quitadamo; Paul J Peters; Alexander Repik; Olivia O'Connell; Zhongming Mou; Matthew Koch; Mohan Somasundaran; Robin Brody; Katherine Luzuriaga; Aaron Wallace; Shixia Wang; Shan Lu; Sean McCauley; Jeremy Luban; Maria Duenas-Decamp; Maria Paz Gonzalez-Perez; Paul R Clapham
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

6.  HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

Authors:  Susan M Schader; Susan P Colby-Germinario; Peter K Quashie; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Thibault Mespléde; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

7.  Assembly and characterization of gp160-nanodiscs: A new platform for biochemical characterization of HIV envelope spikes.

Authors:  Eri Nakatani-Webster; Shiu-Lok Hu; William M Atkins; Carlos Enrique Catalano
Journal:  J Virol Methods       Date:  2015-09-28       Impact factor: 2.014

8.  Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

Authors:  Thaddeus M Davenport; Della Friend; Katharine Ellingson; Hengyu Xu; Zachary Caldwell; George Sellhorn; Zane Kraft; Roland K Strong; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

9.  The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity.

Authors:  Nicholas M Provine; Wendy Blay Puryear; Xueling Wu; Julie Overbaugh; Nancy L Haigwood
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

10.  Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.

Authors:  Ann J Hessell; Delphine C Malherbe; Franco Pissani; Sean McBurney; Shelly J Krebs; Michelle Gomes; Shilpi Pandey; William F Sutton; Benjamin J Burwitz; Matthew Gray; Harlan Robins; Byung S Park; Jonah B Sacha; Celia C LaBranche; Deborah H Fuller; David C Montefiori; Leonidas Stamatatos; D Noah Sather; Nancy L Haigwood
Journal:  J Immunol       Date:  2016-03-04       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.